Compare Medpace Holdings Inc (MEDP) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Medpace Holdings Inc trades at $614.63 (market cap $16.82B), while Consumer Staples Select Sector SPDR Fund trades at $83.24 (market cap $13.50B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| MEDP | XLP | |
|---|---|---|
Market Cap | $16.82B | $13.50B |
Volume | 223,093 | 14,599,953 |
Sector | Health | — |
52-Week High | $630.19 | $90.00 |
52-Week Low | $393.42 | $75.61 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.
The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
